epicatechin has been researched along with Alzheimer Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carver, JA; Duggan, PJ; Ecroyd, H; Liu, Y; Meyer, AG; Tranberg, CE | 1 |
| Bulic, B; Mandelkow, E; Pickhardt, M | 1 |
| Carver, JA; Dehle, FC; Liu, Y; Musgrave, IF; Pukala, TL; Williams, DM | 1 |
1 review(s) available for epicatechin and Alzheimer Disease
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; Protein Binding; Protein Conformation; Structure-Activity Relationship; tau Proteins | 2013 |
2 other study(ies) available for epicatechin and Alzheimer Disease
| Article | Year |
|---|---|
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Caseins; Flavonoids; Humans; Methylation; Milk; Structure-Activity Relationship | 2010 |
Gallic acid is the major component of grape seed extract that inhibits amyloid fibril formation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Gallic Acid; Grape Seed Extract; Mice; Protein Folding | 2013 |